Effects of interleukin-1 antagonism on cortisol levels in individuals with obesity: a randomized clinical trial

Effects of interleukin-1 antagonism on cortisol levels in individuals with obesity: a randomized clinical trial

Background: Anti-inflammatory treatment with interleukin-1 (IL-1) antagonism decreases both cortisol and adrenocorticotropin hormone (ACTH) levels in individuals with obesity in short term. However, it remains unknown whether these effects persist upon prolonged treatment. Methods: In this double-...

Full description

Bibliographic Details
Main Authors: Fahim Ebrahimi, Sandrine A Urwyler, Philipp Schuetz, Beat Mueller, Luca Bernasconi, Peter Neyer, Marc Y Donath, Mirjam Christ-Crain
Format: Article
Language:English
Published: Bioscientifica 2019-05-01
Series:Endocrine Connections
Subjects:
metabolic syndrome
inflammation
interleukin-1
HPA axis
anakinra
Online Access:https://ec.bioscientifica.com/view/journals/ec/8/6/EC-19-0201.xml

Internet

https://ec.bioscientifica.com/view/journals/ec/8/6/EC-19-0201.xml

Similar Items